I love it.

And it's in San Diego this year, so I think that we definitely have the right venue for what will be, as you said, uh, the best ever TCT.

You know, this year, in my mind, I would say that you, you know, if you had to pick one day to be there, at least for me, I would be there on Monday.

Monday is white sneaker day.

Monday is the day that we're gonna be showing some of the best clinical trials that we've ever presented at TCT before.

Undoubtedly, are gonna be practice-changing.

Monday is the day that we're gonna be visited by the creator of Ted Lasso, and Monday is the day that gives us an opportunity to be able to think in a very creative way about where we've been, what we've done, and where we're going.

But what do you think in the field of structural where we're gonna be really excited about pushing us forward beyond what we already know in TAVR?

So having lived through all this, I'll be interested in what your perspectives are about the whole process and where we stand right now and any concerns you may have.

Mike, thank you.

I think that's a bit of a setup.

Well, first, I don't represent the Cardiovascular Research Foundation.

I learned that from somebody.

I know.

I'm not representing the Heart and Valve Collaboratory.

if, it's when, and then the agency's going to react one way or another and how this worked out.